KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Cash & Equivalents (2016 - 2025)

Bausch Health Companies (BHC) has disclosed Cash & Equivalents for 17 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 10.84% to $1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Dec 2025, up 10.84% year-over-year, with the annual reading at $1.3 billion for FY2025, 10.84% up from the prior year.
  • Cash & Equivalents hit $1.3 billion in Q4 2025 for Bausch Health Companies, roughly flat from $1.3 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.7 billion in Q2 2025 to a low of $486.0 million in Q3 2022.
  • Historically, Cash & Equivalents has averaged $853.0 million across 5 years, with a median of $704.5 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: crashed 58.53% in 2023 and later skyrocketed 190.25% in 2025.
  • Year by year, Cash & Equivalents stood at $582.0 million in 2021, then dropped by 3.09% to $564.0 million in 2022, then surged by 67.91% to $947.0 million in 2023, then rose by 24.71% to $1.2 billion in 2024, then increased by 10.84% to $1.3 billion in 2025.
  • Business Quant data shows Cash & Equivalents for BHC at $1.3 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.7 billion in Q2 2025.